Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

4-(N)-Docosahexaenoyl 2’, 2’-difluorodeoxycytidine induces immunogenic cell death in colon and pancreatic carcinoma models as a single agent

Cancer Chemotherapy and Pharmacology(2021)10.1007/s00280-021-04367-2Source: DataRank Database

4-(N)-Docosahexaenoyl 2’, 2’-difluorodeoxycytidine induces immunogenic cell death in colon and pancreatic carcinoma models as a single agent is a research paper published in Cancer Chemotherapy and Pharmacology (2021). On theSindex it has a DataRank of 0. It has been cited 3 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access3 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (6 grants)Impact (FWCI 0.39)OA: greenTopics (80)IDs (PubMed, PMC, OpenAlex)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (7)

Haiyue Xu ORCID,Michael F. Colemam,Solange A. Valdes,Kristyn A. Liu,Stephen D. Hursting ORCID

Live enrichment

PubMed:34698902 PMC:PMC8741741 OpenAlex:https://openalex.org/W3209161233

National Institutes of Health

Grant: CA135274

National Institutes of Health

Grant: CA179362

NCI NIH HHS

Grant: R01 CA135274

NCI NIH HHS

Grant: R21 CA179362

National Institutes of Health

Grant: 2R01CA135274-06A1

Overcoming pancreatic tumor resistance to gemcitabine

National Institutes of Health

Grant: 1R21CA179362-01A1

A Creative Integration of Omega-3 Fatty Acids into Pancreatic Cancer Chemotherapy

FWCI

0.39

Citation Percentile

0.6%

Citation Trend

2023

2024

greenLicense: Springer TDM

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/8741741

publisherhttps://link.springer.com/content/pdf/10.1007/s00280-021-04367-2.pdf

publisherhttps://link.springer.com/article/10.1007/s00280-021-04367-2/fulltext.html

journalhttps://doi.org/10.1007/s00280-021-04367-2

Fields of Study

Advanced Glycation End Products researchAdenosine and Purinergic SignalingImmune cells in cancer0301 basic medicine03 medical and health sciencesAnimalsFemaleHumansMaleAntibodies, MonoclonalAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsCell Line, TumorColonic NeoplasmsDrug Screening Assays, AntitumorGene Expression Regulation, NeoplasticHMGB1 ProteinImmune Checkpoint InhibitorsImmunogenic Cell DeathMice, Inbred BALB CMice, Inbred C57BLPancreatic NeoplasmsProgrammed Cell Death 1 ReceptorMiceAmidesPyrimidines

MeSH Terms

Immunogenic Cell DeathImmune Checkpoint InhibitorsAmidesAnimalsAntibodies, MonoclonalAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsColonic NeoplasmsDrug Screening Assays, AntitumorFemaleHumansMaleMice, Inbred BALB CMice, Inbred C57BLPancreatic NeoplasmsPyrimidinesGene Expression Regulation, NeoplasticHMGB1 ProteinCell Line, TumorMiceProgrammed Cell Death 1 Receptor

Keywords

Cancer researchProgrammed cell deathCarcinomaInternal medicineMedicineBiologyApoptosisBiochemistryCancerPolyunsaturated fatty acidgemcitabineImmunogenic Cell DeathRna ExpressionAnti-pd-1 MabsMaleMice, Inbred BALB CProgrammed Cell Death 1 ReceptorAntibodies, MonoclonalAntineoplastic AgentsAmidesGene Expression Regulation, NeoplasticMice, Inbred C57BLPancreatic NeoplasmsMiceCell Line, TumorAntineoplastic Combined Chemotherapy ProtocolsColonic NeoplasmsAnimalsHumansFemaleDrug Screening Assays, AntitumorHMGB1 ProteinImmune Checkpoint Inhibitors

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being